Autori: Cataldi F
| Naslov | Impact of age of subjects on the efficacy and safety of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials (Meeting Abstract) |
| Autori | Magro F Tilg H Cataldi F Jacobstein D Rabbat C Shan K Nancey S Markovic S Rocco R Harlacher L Yarur A |
| Info | JOURNAL OF CROHNS & COLITIS, (2026), vol. 20 br. , Suppl. _1, str. - |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | Early symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials (Meeting Abstract) |
| Autori | Armuzzi A Atreya R Sparrow MP Markovic S Le Berre C Hlavaty T Treton X Cataldi F Jacobstein D Rabbat C Shan K Dubinsky MC |
| Info | JOURNAL OF CROHNS & COLITIS, (2026), vol. 20 br. , Suppl. _1, str. - |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn's disease: the OPERA II study (Meeting Abstract) |
| Autori | D'Haens Geert R Reinisch Walter Lee SD Tarabar Dino K Louis E Klopocka M Klaus J Schreiber S Park DI Hebuterne Xavier Cataldi F Banerjee A Gorelick K Sandborn William J |
| Info | JOURNAL OF CROHNS & COLITIS, (2018), vol. 12 br. , Suppl. 1, str. S17-S18 |
| Ispravka | ISI/Web of Science Elečas Rang časopisa Citati: ISI/Web of Science |
